Objective-Low concentrations of prostaglandin (PG) E 2 enhance platelet aggregation, whereas high concentrations inhibit it. The effects of PGE 2 are mediated through 4 G protein-coupled receptors, termed E-type prostaglindin (EP) receptor EP1, EP2, EP3, and EP4. The platelet-stimulating effect of PGE 2 has been suggested to involve EP3 receptors. Here we analyzed the receptor usage relating to the inhibitory effect of PGE 2 . Methods and Results-Using flow cytometry, we found that human platelets expressed EP4 receptor protein. A selective EP4 agonist (ONO AE1-329) potently inhibited the platelet aggregation as induced by ADP or collagen. This effect could be completely reversed by an EP4 antagonist, but not by PGI 2 , PGD 2 , and thromboxane receptor antagonists or cyclooxygenase inhibition. Moreover, an EP4 antagonist enhanced the PGE 2 -induced stimulation of platelet aggregation, indicating a physiological antiaggregatory activity of EP4 receptors. The inhibitory effect of the EP4 agonist was accompanied by attenuated Ca 2ϩ flux, inhibition of glycoprotein IIb/IIIa, and downregulation of P-selectin. Most importantly, adhesion of platelets to fibrinogen under flow and in vitro thrombus formation were effectively prevented by the EP4 agonist. In this respect, the EP4 agonist synergized with acetylsalicylic acid. Key Words: aspirin Ⅲ pharmacology Ⅲ platelet receptor blockers Ⅲ platelets Ⅲ prostacyclin Ⅲ prostaglandins Ⅲ thromboxanes S ubjects with increased platelet reactivity are at increased prospective risk for coronary events and death. A number of pathophysiological states, such as atherosclerosis, diabetes, and metabolic syndrome, are associated with increased platelet reactivity and thrombogenic potential. Under inflammatory conditions, the synthesis of prostanoids in endothelial cells and smooth muscle cells is highly increased. Predominantly, the biosynthesis of prostaglandin (PG) E 2 is enhanced in vascular smooth muscle cells 1 and macrophages 2,3 by inflammatory mediators.
S
ubjects with increased platelet reactivity are at increased prospective risk for coronary events and death. A number of pathophysiological states, such as atherosclerosis, diabetes, and metabolic syndrome, are associated with increased platelet reactivity and thrombogenic potential. Under inflammatory conditions, the synthesis of prostanoids in endothelial cells and smooth muscle cells is highly increased. Predominantly, the biosynthesis of prostaglandin (PG) E 2 is enhanced in vascular smooth muscle cells 1 and macrophages 2, 3 by inflammatory mediators.
Prostanoids are involved in hemostasis by differentially influencing platelet aggregation. Although thromboxane (TX) A 2 , produced in platelets, and PGH 2 , released untransformed from activated/dysfunctional endothelium, are potent stimulators of platelet aggregation, 4 PGI 2 and PGD 2 are known to inhibit platelet aggregation. 5 PGE 2 shows a biphasic, concentration-dependent effect on platelet aggregation. Although high concentrations inhibit platelet aggregation, lower concentrations enhance it. 6 -11 PGE 2 binds and activates 4 G protein-coupled receptors, EP1, EP2, EP3, and EP4. Each of these receptors has a distinct pharmacological signature and intracellular signal transduction. 12, 13, 14 Stimulation of the EP3 receptors results in elevation of free intracellular Ca 2ϩ levels, whereas stimulation of the EP2 and EP4 receptors usually increases intracellular cAMP levels through activation of G s protein, 12 resulting in a decrease of intracellular Ca 2ϩ levels. Human platelets contain mRNA for EP1 receptors, all of the EP3 splice variants, and EP4; however, mRNA for EP2 receptors is lacking in platelets. 15 The proaggregatory effect of PGE 2 has been ascribed to the activation of the EP3 receptor, leading to inhibition of the increase in cAMP, 16, 17 an increased mobilization of Ca 2ϩ , 18 and increased P-selectin expression on platelets. 19, 20 An EP3 antagonist has been proposed to be useful for antithrombotic therapy. 19 Here we demonstrate that a selective EP4 agonist inhibits platelet aggregation, Ca 2ϩ mobilization, and upregulation of P-selection. In November 2009, we first reported these novel findings in a meeting abstract. 21 Thereafter, while the current report was in preparation, 3 articles were published that overlap with the data in our abstract and fully confirm our findings, as they report that an EP4 antagonist reverses the inhibition by PGE 2 of U46619-induced platelet aggregation 22 ; that the EP4 agonist ONO AE1-329 prevents the platelet-activating factor (PAF)-induced platelet aggregation, U46619-induced P-selectin upregulation, and thrombin receptor-mediated Ca 2ϩ flux in platelets 23 ; and that murine platelets are less sensitive to EP4 activation than human platelets. 24 Regrettably, none of these authors acknowledged our work. In excess of these observations, we report here that (1) platelets express EP4 receptor protein, (2) activation of EP4 receptors counteracts the activation of glycoprotein [GP] IIb/IIIa, and (3) hence prevents the binding of platelets to fibrinogen. Moreover, (4) these inhibitory effects of the EP4 receptor on platelet activation translate to potent antithrombotic activity of the EP4 agonist as shown by in vitro thrombus formation assays using whole blood, and (5) EP4 activation enhances the inhibitory effect of acetylsalicylic acid. Therefore, we propose that selective EP4 receptor agonists may provide a novel antithrombotic strategy in humans.
Materials and Methods
Reagents are described in the supplemental materials, available online at http://atvb.ahajournals.org.
Platelet Aggregation
This study was approved by the ethics committee of the Medical University of Graz. Before blood sampling from healthy volunteers, all donors signed an informed consent form. Human platelet-rich and platelet-poor plasma were prepared from citrated whole blood by centrifugation. Platelet aggregation was recorded at 37°C with constant stirring (1000 rpm) in an Aggrecorder-II (KDK Corp, Kyoto, Japan) as described. [25] [26] [27] Platelet aggregation was measured as the increase in light transmission for 5 minutes, starting with the addition of ADP (2.5 to 20 mol/L) or collagen (1.25 to 10 g/mL) as proaggregatory stimulus. CaCl 2 at a final concentration of 1 mmol/L was added 2 minutes before ADP or collagen. In some experiments acetylsalicylic acid (1 mmol/L as lysine acetylsalicylic acid) was added to platelet rich plasma 30 minutes before the proaggregatory stimulus. To record inhibition of agonist-induced aggregation, PGE 2 or other compounds were added 2 minutes before ADP or collagen. The antagonists or their vehicle were added 10 minutes before the respective agonist. Data were expressed as percentage of maximum light transmission, with nonstimulated platelet-rich plasma being 0% and platelet-poor plasma 100%.
Ca

2؉ Flux
Intracellular Ca 2ϩ levels were analyzed by flow cytometry as described. [27] [28] [29] Washed platelets were loaded with 5 mol/L of the acetoxymethyl ester of Fluo-3 in the presence of 2.5 mmol/L probenecid at 37°C for 30 minutes and were then resuspended in PBS containing 0.9 mmol/L Ca 2ϩ and 0.5 mmol/L Mg 2ϩ . Changes in intracellular free Ca 2ϩ levels in response to ADP (10 to 1000 nmol/L) were detected as increase in fluorescence intensity of the Ca 2ϩ -sensitive dye Fluo-3 in the FL-1 channel.
Flow Cytometric Immunofluorescence Staining
Washed platelet preparations were fixed, permeabilized, and blocked using Ultra V blocking solution. Staining was done using an EP4 antibody or control IgG antibody (20 g/mL) for 30 minutes on ice and subsequently incubated with an anti-rabbit Alexa Fluor-488 conjugated secondary antibody (4 g/mL), with the required washing steps. The samples were read on a FACSCalibur flow cytometer (Becton Dickinson). To record P-selectin expression, platelets were activated by ADP (3 mol/L) in the presence cytochalasin B (5 g/mL) for 15 minutes at 37°C in the presence of the anti-CD62P-fluorescein isothiocyanate antibody. 30 The samples were washed and fixed, and CD62P (P-selectin) upregulation was detected by flow cytometry. Activation of the fibrinogen receptor GPIIb/IIIa was assayed using the PAC-1 antibody, which recognizes a conformation-dependent determinant on the GPIIb/IIIa complex. 
Platelet Adhesion
Vena8 biochips (Cellix Ltd, Dublin, Ireland) were coated with fibrinogen (100 g/mL) at 4°C overnight. On the next day, the chips were blocked with BSA (10 g/mL) for 30 minutes at room temperature and then washed once more with PBS containing 0.9 mmol/L Ca 2ϩ and 0.5 mmol/L Mg 2ϩ . Eighty-microliter aliquots of platelet-rich plasma were pretreated with vehicle, iloprost (3 nmol/L), or ONO AE1-329 (300 nmol/L) for 5 minutes. Aliquots were then mixed with ADP (10 mol/L) in the presence of 1 mmol/L CaCl 2 (10 L) and then immediately perfused over the fibrinogencoated channels at constant shear stress of 0.5 dyne cm Ϫ2 for 3 minutes using the Mirus nanopump (Cellix). Platelet adhesion was recorded on an Olympus IX70 fluorescence microscope and an Olympus UPlanFI-ϫ20/0.40 lens, using a Hamamatsu ORCA-ER digital camera and the Olympus CellP software. Cell images of 3 microscopic fields from each channel were captured, and images were analyzed using DucoCell software (Cellix).
In Vitro Thrombogenesis
Vena8Fluoroϩ Biochips (Cellix) were coated with collagen (200 g/mL) at 4°C overnight. Blocking was performed with bovine serum albumin (10 g/mL) for 30 minutes at room temperature followed by washing steps. Whole blood collected in 3.8% sodium citrate was incubated with 3,3Ј-dihexyloxacarbocyanine iodide (1 mol/L) in the dark for 10 minutes. To record inhibition of thrombus formation, whole blood was treated with PGE 2 (10 mol/ L), the EP4 agonist ONO AE1-329 (300 nmol/L), or acetylsalicylic acid (1 mmol/L) for 10 minutes before the perfusion was started. The EP4 antagonist (ONO AE3-208; 1 and 10 mol/L) or its vehicle was added 10 minutes before the respective agonist. CaCl 2 at a final concentration of 1 mmol/L was added 2 minutes before the perfusion over the collagen-coated chip. Perfusion at a shear rate of 30 dynes cm Ϫ2 and microscopy were carried out as described above for platelet adhesion.
Statistical Analyses
Data are shown as meanϮSEM for n observations. Comparisons of groups were performed using 1-way or 2-way ANOVA with the Dunnett post test or the Wilcoxon signed rank test. Probability values of PϽ0.05 were considered statistically significant.
Results
EP4 Receptor Stimulation Inhibits Platelet Aggregation
First, we tested the hypothesis that activation of EP4 receptors modulates platelet aggregation. Platelet-rich plasma was treated with various concentrations of the EP4 selective agonist ONO AE1-329 (0.01 to 300 nmol/L) for 7 minutes before ADP or collagen was added to induce platelet aggregation. The concentrations of ADP (2.5 to 20 mol/L) and collagen (1.25 to 10 g/mL) were adjusted to give submaxi-mal aggregation. ONO AE1-329 itself did not induce platelet aggregation at concentrations up to 1 mol/L (nϭ6, data not shown) but concentration-dependently attenuated both the ADP-and collagen-induced aggregation ( Figure 1A and 1B). To investigate the role of EP4 receptors in the PGE 2 -induced effects on platelet function, samples were pretreated with the EP4 antagonist ONO AE3-208 (300 nmol/L) for 10 minutes and then treated with PGE 2 (3 to 300 nmol/L) for 7 minutes. Finally, platelet aggregation was initiated with ADP at concentrations that yielded half-maximal platelet aggregation. PGE 2 alone did not trigger platelet aggregation under these conditions (nϭ6, data not shown) but slightly enhanced the ADP-induced aggregation. This effect was dramatically enhanced in the presence of the EP4 antagonist ( Figure 1C) . A similar observation was made when collagen was used as a proaggregatory stimulus (nϭ6, data not shown). Consistently, EP4 receptor protein was detectable on platelets in flow cytometry as revealed by a polyclonal anti-EP4 antibody that gave considerably higher staining than the respective isotype-matched control antibody ( Figure 1D) .
In further experiments, we addressed the possibility that the inhibitory effect of the EP4 agonist ONO AE1-329 was mediated by alternative inhibitory PG receptors such as the EP2 receptor, I-prostanoid receptor (IP), or D-prostanoid receptor (DP). Butaprost, a selective EP2 agonist at concentrations up to 300 nmol/L, did not mimic the inhibitory effect of the EP4 agonist, as it left the ADP-induced aggregation unaltered (Figure 2A) . Pretreatment of the samples with the IP antagonist CAY10441 (300 nmol/L) or the DP antagonist BWA868c (1 mol/L) did not attenuate the inhibitory effect of the EP4 agonist ONO AE1-329 ( Figure 2B ). To exclude the possibility that the inhibitory effect of ONO AE1-329 was due to modulation of the thromboxane receptor (TP) or prostanoid release from platelets, samples were pretreated with acetylsalicylic acid (1 mmol/L) or with the TP antagonist SQ29548 (1 mol/L). Although both compounds per se moderately reduced the ADP-induced aggregation by 20% to 30% (PϽ0.05, nϭ6, data not shown), they did not influence the inhibitory effect of the EP4 agonist ONO AE1-329 ( Figure 2C) . Moreover, the EP4 antagonists ONO AE3-208 (300 nmol/L and 1 mol/L) and GW627368x (10 mol/L) both reversed the inhibitory effect of the EP4 agonist ( Figure  2D ). Conversely, ONO AE3-208 and GW627368x had no effect on the iloprost-induced inhibition of platelet aggregation ( Figure 2E ). The proaggregatory effect of EP3 stimulation was confirmed by the EP3 agonist sulprostone, which potently enhanced the ADP-induced aggregation (Figure 2A) , reminiscent of the proaggregatory effect of PGE 2 in the presence of the EP4 antagonist shown in Figure 1C .
Next, we investigated whether platelets from rats, guinea pigs, and mice responded to activation of EP4 receptors. In fact, flow cytometric immunostaining showed that platelets from all 3 species expressed EP4 receptors (Supplemental Figure I) . Unexpectedly, the EP4 agonist ONO AE1-329 at a concentration of 300 nmol/L was unable to inhibit ADPinduced aggregation in any of the 3 species, although iloprost was effective (Supplemental Figure II) . Collectively, these data suggested that, in contrast to rodents, EP4 receptors on human platelets play a prominent antiaggregatory role.
Cellular Mechanisms Linked to EP4-Mediated Inhibition of Platelet Aggregation
Because platelet aggregation essentially depends on increased free intracellular Ca 2ϩ levels, we investigated how EP4 receptors modulate Ca 2ϩ responses to ADP using a flow cytometric Ca 2ϩ flux assay. ADP was highly efficient to stimulate Ca 2ϩ flux in platelets in a concentration-dependent manner (10 to 1000 nmol/L). Whereas iloprost caused almost complete inhibition, ONO AE1-329 significantly attenuated this response ( Figure 3A) . Similarly, PGE 2 in the concentration range of 0.1 and 10 mol/L reduced the Ca 2ϩ responses to 100 nmol/L ADP. This effect of PGE 2 was largely prevented in the presence of the EP4 antagonist GW627368x ( Figure 3B ).
Because elevation of intracellular free Ca 2ϩ levels is crucial for upregulation of P-selectin and activation of GPIIb/ IIIa, we further investigated the effects of EP4 activation on these responses. Stimulation of platelets with ADP (3 mol/L) increased the surface expression of CD62P 8-fold as detected by an anti-CD62P antibody directly conjugated to fluorescein isothiocyanate ( Figure 3C ). The activation of GPIIb/IIIa was detected with the use of a conformationdependent antibody, PAC-1 ( Figure 3D ). ONO AE1-329 (300 nmol/L) effectively prevented the CD62P upregulation and the activation of GPIIb/IIIa. In contrast, relatively high concentrations of PGE 2 (10 mol/L) were required to achieve similar inhibition. The TP antagonist SQ29548 (100 nmol/L) by itself had no effect on ADP-induced CD62P upregulation and activation of GPIIb/IIIa (data not shown) and also did not prevent the inhibition obtained by ONO AE1-329 (300 nmol/L; Figure 3C and 3D). The inhibitory effects of PGE 2 (10 mol/L) and the EP4 agonist ONO AE1-329 (300 nmol/L) were also seen in platelets treated with acetylsalicylic acid (1 mmol/L; Figure 3E and 3F). To further substantiate the role of EP4 receptors, platelets were pretreated with the EP4 antagonist ONO AE3-208 (1 or 10 mol/L), which abolished the inhibitory effects of the EP4 agonist ONO AE1-329 and PGE 2 ( Figure 3E and 3F) . The total amount GPIIb/IIIa was not changed by any of these treatments as determined using an anti-CD41 antibody ( Supplemental Figure III) . These observations suggest that activation of EP4 receptors attenuates platelet aggregation by the control of Ca 2ϩ mobilization and the ensuing upregulation of P-selectin and activation of GPIIb/IIIa.
Effect of EP4 Activation on Platelet Adhesion and In Vitro Thrombus Formation
Because we observed that stimulation of EP4 receptors downregulates the expression of adhesion molecules and prevents activation of the fibrinogen receptor GPIIb/IIIa, we investigated the adhesion of platelets to fibrinogen under flow conditions. Platelet-rich plasma was perfused under shear stress over fibrinogen-coated surfaces, and platelet adhesion was recorded by microscopy. Addition of 10 mol/L ADP to the samples rapidly triggered the adhesion of platelets to fibrinogen within 3 minutes ( Figure 4A ). In samples treated with ONO AE1-329 (300 nmol/L), this was largely prevented, and only individual small aggregates were observed. Iloprost (3 nmol/L) likewise prevented platelet adhesion. Computerized image analysis of the photographs taken after 3 minutes of platelet perfusion confirmed that the EP4 agonist reduced the platelet-covered area by 90% ( Figure 4B ).
Finally, we assessed whether EP4 activation also prevented thrombogenesis. To this end, whole blood was perfused through collagen-coated channels, and thrombus formation was recorded by fluorescence microscopy. Adhesion of platelets to collagen was observed after 1 minute, subsequently leading to pronounced thrombus formation as shown in Figure 5 at 3 minutes. In samples pretreated with the EP4 agonist ONO AE1-329 (300 nmol/L) or PGE 2 (10 mol/L), thrombus formation was largely prevented, and only small aggregates were observed ( Figure 5A ). The effects of the EP4 agonist and PGE 2 were reversed by the EP4 antagonist ONO AE3-208 (1 mol/L and 10 mol/L). As expected, thrombus formation was likewise attenuated by acetylsalicylic acid (1 mmol/L), and its combination with the EP4 agonist ONO AE1-329 almost completely abolished the thrombus formation ( Figure 5A ). Computerized image analysis revealed that the EP4 agonist reduced the area of the thrombi by 79%, whereas the combination of ONO AE1-329 plus acetylsalicylic acid reduced it by 93% ( Figure 5B ).
Discussion
In the present study, we suggest a novel path for antithrombotic intervention, as we show that EP4 receptors expressed on human platelets confer inhibitory signals. On the one hand, we observed that EP4 receptors play an important role in the complex action of PGE 2 in the regulation of platelet function, because an EP4 antagonist accentuated the PGE 2 -induced enhancement of agonist-induced platelet aggregation. On the other hand, selective stimulation of EP4 receptors using an EP4 agonist potently inhibited platelet aggregation in response to ADP or collagen. Furthermore, we could decipher the cellular mechanisms linked to EP4- mediated platelet inhibition: ligation of EP4 receptors apparently attenuates Ca 2ϩ mobilization in platelets and curbs the agonist-induced upregulation of P-selectin and the dimerization/activation of the fibrinogen receptor GPIIb/IIIa. On a functional level, these changes lead to a reduced capacity of platelets to adhere to surfaces and to form thrombi under flow conditions. PGE 2 has long been known to attenuate platelet aggregation at high concentrations, ie, in the micromolar range; at lower concentrations, however, PGE 2 is promoting aggregatory responses induced by platelet activators, such as ADP or collagen. 6, 7, 9, 10, 32 Therefore, the primary action of PGE 2 was suggested to be proaggregatory. The EP3 receptor was subsequently characterized as the receptor that mediates the PGE 2 -induced augmentation of platelet aggregation, and EP3 receptor antagonists are currently under consideration as potential novel antithrombotic treatment. 19 This notion was also confirmed in our study, because the EP3 agonist sulprostone potently enhanced the ADP-induced platelet aggregation with an estimated EC 50 below 3 nmol/L. How the inhibitory role of EP4 receptors has until now gone unnoticed might be explained by studies in PGE 2 receptor and IP knockout mice, suggesting that it is the IP rather than EP2 or EP4 receptors that underlie the inhibitory effect of PGE 2 on murine platelet aggregation. 24, 33 In the current study, we show for the first time that human platelets express EP4 receptors, which is in line with a previous report of EP4 mRNA detected in platelets. 15 Led by this observation, we tested an EP4 selective agonist, ONO AE1-329, in assays of platelet aggregation. In fact, ONO AE1-329 potently attenuated agonist-induced platelet aggregation with apparent IC 50 values of 3 and 0.1 nmol/L against the proaggregatory stimuli ADP and collagen, respectively. Conversely, 2 chemically distinct EP4 antagonists, GW627368x and ONO AE3-208, abrogated the inhibitory effect of ONO AE1-329 on platelet aggregation. Moreover, the specific IP and DP antagonists, CAY10441 and BWA868c, showed no tendency to reverse the inhibitory effect of the EP4 agonist, although they prevented the inhibitory effects of the IP agonist iloprost (this study) and the DP agonist PGD 2 . 27 Similarly, the TP antagonist SQ29548 or acetylsalicylic acid had no effect on the EP4-mediated inhibition of platelet aggregation. Therefore, these data unequivocally demonstrate that selective activation of EP4 receptors on platelets restrains platelet aggregation in humans without involving other inhibitory prostanoid receptors or modulating thromboxane A 2 release or TP activity.
ONO AE1-329 had no inhibitory effect on platelets from rats, guinea pigs, and mice, although iloprost was effective in all 3 species (cf. supplemental data). One possible explanation might be the expression levels of EP4, which appeared to be lower in rodent platelets compared with human platelets. Therefore, these observations precluded further experimentation in animal models of thrombogenesis. Instead, we used an in vitro model of platelet adhesion and thrombus formation, which allows quantification of platelet function under flow conditions. 34, 35 In fact, adhesion of platelets and subsequent thrombogenesis were effectively prevented by the EP4 agonist.
Agonist-induced Ca 2ϩ flux was also attenuated by the EP4 agonist and also by PGE 2 , and this effect was largely prevented by the EP4 antagonist GW627368x. However, the effect of EP4 receptor activation on Ca 2ϩ flux was considerably smaller compared with the pronounced inhibition of platelet aggregation, suggesting that additional mechanisms are likely to be in place. P-selectin (CD62P) plays an important role in the interaction of platelets with leukocytes and endothelial cells and is upregulated in activated platelets. The ultimate step in platelet aggregation is activation of GPIIb/IIIa, which then binds fibrinogen with high avidity and thus enables thrombus formation. Most substantially, the EP4 agonist ONO AE1-329 and, to a lesser extent, PGE 2 were able to prevent the agonist-induced upregulation of P-selectin and activation of GPIIb/IIIa. Again, the EP4 antagonist completely abolished the inhibitory effect of the EP4 agonist on upregulation of P-selectin and GPIIb/IIIa activation, whereas the TP antagonist and acetylsalicylic acid had no effect. These observations were in good agreement with reduced platelet adhesion to fibrinogen, the ligand of GPIIb/ IIIa. Finally, flow chamber experiments using perfusions of human whole blood over collagen confirmed that the inhibitory effects of ONO AE1-329 on platelet function translated to potent antithrombogenic effects. In this respect, the EP4 agonist matched the effect of acetylsalicylic acid, and in combination even enhanced the inhibitory effect of that clinically relevant antiplatelet drug.
EP4 receptors have been shown to couple to G s proteins and adenylyl cyclase-mediated cAMP production. 14 The antiaggregatory effects of PGI 2 and PGD 2 have been demonstrated to rely on cAMP and subsequent attenuation of Ca 2ϩ mobilization, 36 -39 suggesting that cAMP is an important negative regulator of platelet function. Unexpectedly, we observed that pretreatment with the adenylyl cyclase inhibitor SQ22536 (100 mol/L) was unable to prevent the inhibitory effect of ONO AE1-329 on platelet aggregation (data not shown, nϭ6). The disparity of IP and EP4 signaling with respect to the adenylyl cyclase/cAMP pathways might thus account for the higher potency of iloprost as platelet inhibitor. In contrast, the nonselective protein kinase C (PKC) inhibitor chelerythrine (100 mol/L) abolished the EP4-mediated effects on platelets (data not shown, nϭ6), which was in line with PKC being linked to EP4 signaling in HL-60 cells and eosinophils. 40, 41 PKC is a major regulator of platelet granule secretion, integrin activation, and aggregation, whereby individual members of the PKC family play distinct, sometimes opposing roles. 42 For instance, PKC-␣, a classic isoform, is an essential positive regulator of granule secretion and thrombus formation, 43 whereas the novel isoform PKC-␦ negatively regulates filopodia formation and thromboxane A 2 release and thus reduces platelet aggregation and thrombus formation. 44, 45 Therefore, the involvement of PKC isoforms in EP4 signaling of platelets remains a substantial field for further investigation.
In conclusion, our data suggest that EP4 receptors might play an important role in the control of hemostasis by mediating the inhibitory effect of PGE 2 , thereby balancing out the proaggregatory effect of EP3 receptors. When activated separately using selective agonists, EP4 receptors afford potent inhibition of platelet function with respect to platelet adhesion, aggregation, and thrombus formation. Hence, EP4 agonists might constitute a novel class of antithrombotic agents and might be clinically useful in cases where acetylsalicylic acid or ADP antagonists are not warranted or are insufficient.
